Daruharidra

<h3> Absolute Contraindications of Daruharidra </h3> <h4>Pregnancy (avoid while pregnant)</h4> <ul> <li> 🤰 <li> Recommendation: Do not use Daruharidra/berberine during pregnancy; discontinue supplements that contain it and seek medical advice. <li> Reasoning: Preclinical and clinical toxicology reviews report uterine stimulation, developmental effects at high doses in animals and concerns about fetal exposure; safety in human pregnancy is not established. <li> Scientific_Study_Title: Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review <li> Scientific_Study_Authors: Seyede Zohre Kamrani Rad, Maryam Rameshrad, Hossein Hosseinzadeh <li> Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478780/ <li> Scientific_Study_Excerpt: <p>This 2017 toxicology review summarizes animal and human data on berberine and Berberis species. The authors collate evidence that berberine can evoke uterine contractions in experimental systems and that developmental toxicity signals appear at high doses in animal studies. The review notes that teratogenic and maternal toxic doses have been reported in rodents and that, because berberine reaches many tissues and is biologically active, use during pregnancy is not supported. The paper concludes that caution is warranted and that pregnant women should avoid berberine-containing preparations until safety is proven.</p> </ul> <h4>Breastfeeding / Newborn exposure (risk of neonatal jaundice / kernicterus)</h4> <ul> <li> 🍼 <li> Recommendation: Avoid Daruharidra/berberine during breastfeeding; if exposed, discuss with a pediatrician and monitor the infant for jaundice. <li> Reasoning: Berberine can be transferred to infants via breast milk and may displace bilirubin from albumin, raising free bilirubin - this can worsen neonatal jaundice and rarely risk kernicterus. <li> Scientific_Study_Title: Non-Pharmaceutical Intervention Options For Type 2 Diabetes: Complementary & Integrative Health Approaches (chapter discussing safety of natural products) <li> Scientific_Study_Authors: Skye A. McKennon (chapter author); editors Feingold KR et al. <li> Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/books/NBK279062/ <li> Scientific_Study_Excerpt: <p>The Endotext summary on natural products and safety notes that berberine-containing herbs are not recommended during pregnancy or lactation because berberine can cross the placenta and be excreted into breast milk. The chapter highlights reports and mechanistic data showing displacement of bilirubin from albumin and the potential for neonatal hyperbilirubinaemia; it advises against use in late pregnancy and during breastfeeding due to the risk to neonates, especially those with pre-existing jaundice or enzymatic vulnerabilities.</p> </ul> <h4>Infants / G6PD deficiency (newborns and vulnerable infants)</h4> <ul> <li> 🧸 <li> Recommendation: Do not give Daruharidra/berberine to newborns or infants, and avoid it in people known to have G6PD deficiency without specialist advice. <li> Reasoning: Case reports historically linked berberine-rich herbs to severe neonatal jaundice and deaths in G6PD-deficient infants; while evidence quality varies, risk is plausible and potentially severe. <li> Scientific_Study_Title: Adverse effects of herbal or dietary supplements in G6PD deficiency: a systematic review <li> Scientific_Study_Authors: Shaun Wen Huey Lee, Nai Ming Lai, Nathorn Chaiyakunapruk, David Weng Kwai Chong <li> Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC5338162/ <li> Scientific_Study_Excerpt: <p>This systematic review (British Journal of Clinical Pharmacology) examined published reports of herbal and dietary supplements in people with G6PD deficiency. The authors identified case reports and case series where some Chinese herbal preparations (containing berberine alkaloids) were associated with severe neonatal hyperbilirubinaemia and kernicterus in infants with G6PD deficiency in historical reports; because of uncertain product purity, causality is imperfect but the authors recommend caution or avoidance of agents that may increase bilirubin in this vulnerable group.</p> </ul> <h3> Relative Contraindications of Daruharidra </h3> <h4>Concomitant use with CYP and P-gp substrate drugs (e.g., cyclosporine, digoxin, many statins)</h4> <ul> <li> ⚠️ <li> Recommendation: Avoid unsupervised combined use; consult the prescribing clinician or pharmacist for monitoring or dose adjustment. <li> Reasoning: Berberine inhibits intestinal P-gp and reduces activities of CYP enzymes after repeated dosing - this can raise plasma levels of drugs that depend on these pathways and increase toxicity risk. <li> Scientific_Study_Title: Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp <li> Scientific_Study_Authors: W. Qiu, X. H. Jiang, C. X. Liu, Y. Ju, J. X. Jin <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/19370549/ <li> Scientific_Study_Excerpt: <p>In a rat pharmacokinetics study, pretreatment with berberine increased the oral bioavailability of digoxin and cyclosporine A in a dose-dependent manner, consistent with inhibition of intestinal P-glycoprotein (P-gp). After two weeks of berberine, cyclosporine A AUC and Cmax rose significantly; orally given digoxin also showed increased exposure. The authors conclude that berberine can increase systemic exposure of P-gp substrates, and recommend careful use with narrow therapeutic index drugs.</p> </ul> <h4>Diabetes drugs (insulin, sulfonylureas, meglitinides)</h4> <ul> <li> 🩺 <li> Recommendation: If you take prescription glucose-lowering medications, discuss with your clinician before using Daruharidra; blood glucose monitoring and possible dose adjustment may be needed. <li> Reasoning: Berberine itself lowers blood glucose; it also alters metabolism of some sulfonylureas in vitro - together these can increase the risk of hypoglycaemia when combined with anti-diabetic drugs. <li> Scientific_Study_Title: Effect of berberine on in vitro metabolism of sulfonylureas: A herb-drug interactions study <li> Scientific_Study_Authors: (authors as listed on the paper) <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/31721320/ <li> Scientific_Study_Excerpt: <p>This in-vitro study examined how berberine affects the metabolism of sulfonylurea drugs (glyburide, gliclazide). The results showed that berberine and sulfonylureas share common CYP isozymes for metabolism (notably CYP3A and CYP2C), and co-incubation decreased formation of drug metabolites in a concentration-dependent way. The authors conclude that berberine may inhibit sulfonylurea metabolism and could alter their blood levels, suggesting potential for clinically relevant herb-drug interactions and the need for monitoring.</p> </ul> <h4>Anticoagulants / Antiplatelet agents (warfarin, DOACs, aspirin clopidogrel)</h4> <ul> <li> 🩸 <li> Recommendation: Use caution-tell your prescriber if you take Daruharidra; avoid starting it without medical advice and consider closer monitoring (INR for warfarin, bleeding signs for DOACs). <li> Reasoning: Berberine can inhibit CYP enzymes and may affect platelet function; these mechanisms could increase bleeding risk or change anticoagulant levels. <li> Scientific_Study_Title: Repeated administration of berberine inhibits cytochromes P450 in humans <li> Scientific_Study_Authors: Ying Guo, Yao Chen, Zhi-Rong Tan, Curtis D. Klaassen, Hong-Hao Zhou <li> Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/21870106/ <li> Scientific_Study_Excerpt: <p>This randomized crossover human study found that two weeks of oral berberine (300 mg three times daily) inhibited activities of CYP3A4, CYP2D6 and CYP2C9 as measured by standard probe drugs. Because warfarin metabolism depends on CYP2C9 and many anticoagulants are CYP/P-gp substrates, the authors warn that berberine may alter blood levels of co-administered drugs metabolized by these pathways; they recommend considering potential drug-drug interactions in patients taking berberine.</p> </ul>